Skip to main content

Table 6 The Association Between CD8+: FOXP3+ T Cell Ratio (Breast Tumour, ALN Metastases, ALNs(a) and Subsequent PCR Following NAC(b)

From: Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC

Sites

Groups

Median (Range)(c)

P Value(d) (PCR Versus Non PCR)

Primary breast tumours, n = 33 (CD8+: FOXP3+ T cell ratio)

Tumours with pCR

7.40 (0.27-45.00)

0.002e

Tumours with non pCR

1.48 (0.18-6.04)

ALN metastatic tumours, n = 20 (CD8+: FOXP3+ T cell ratio)

Metastatic tumours with pCR

5.87 (1.35-21.92)

0.080

Metastatic tumours with non pCR

1.93 (0.40-7.20)

ALNs, n = 24 (%CD8+: %FOXP3+ T cell ratio)

ALNs with pCR

7.24 (3.33-75.00)

0.006e

ALNs with non pCR

3.19 (1.78-8.00)

  1. (a)ALNs: Axillary lymph nodes (metastatic but tumour-free paracortical area); (b)NAC: Neoadjuvant chemotherapy; (c)Ratio of CD8+:FOXP3+ T cells (see Materials and Methods); (d)Mann-Whitney U test; eStatistically significant